Statins for multiple sclerosis
Timothy Vollmer and colleagues (May 15, p 1007) 1 provide evidence that treatment with 80 mg of simvastatin inhibits the inflammatory components of multiple sclerosis. Their study is not, however, "the first to provide some evidence of an effect with a statin in multiple sclerosis", as stated by Chris Polman and Joep Killestein in their Commentary.
2
In 2003, we reported 3 the results of an observational study of seven female patients who had relapsing-remitting disease after 1 year of monotherapy with 40 mg of lovastatin. In agreement with Vollmer and colleagues' findings, we noted a reduction in the mean number of gadolinium (Gd)-enhancing lesions and no great differences between pretreatment and treatment expanded disability status scores. Three patients remained free of relapses, and the mean annual relapse rate decreased during the year. However, we did detect new lesions on T2-weighted images in five patients at the end of the study. Six people have now completed 2 years of lovastatin monotherapy; three patients had relapses and developed new T2-weighted lesions during the second year of treatment.
Our results suggest that the reduction in Gd-enhancing lesions observed by Vollmer and colleagues after 6 months of treatment cannot ensure an inhibitory effect on the progression of the disease, Timothy Vollmer and colleagues 1 report the effective use of a drug that is generally considered safe in the treatment of relapsing-remitting multiple sclerosis, which is very promising. Although no serious adverse drug effects arose during the study, three patients complained of muscle weakness, one had an increased creatinine phosphokinase concentration, and two had abnormal liverfunction test results. This high proportion of adverse effects could be a direct consequence of the fairly high daily dose of simvastatin used. We caution against the chronic administration of such a high dose.
In 2000 and 2001 (before the cerivastatin withdrawal episode), our Regional
